$NTRA

Natera (NTRA) presented data from the ESMO Congress 2026, showcasing its Signatera assay in 25 abstracts, including 9 oral presentations. The VOLGA trial in bladder cancer showed that Signatera ctDNA dynamics predicted event-free survival, with persistently negative patients having a 24-month EFS rate of 91%. Additional studies in lung, endometrial, and breast cancer were also highlighted, demonstrating the potential of ctDNA testing in guiding treatment decisions.

Natera presented results from the phase III VOLGA trial, showing its Signatera assay predicted 24-month event-free survival rates of 91%, 81%, or 55% in bladder cancer patients. The assay was also highlighted in other trials for lung, endometrial, and breast cancers. Natera's tests aim to guide treatment decisions and improve outcomes.

BTIG raised its price target on Natera (NTRA) to $430 from $320, citing strong revenue growth expectations. The firm anticipates a 7% revenue beat in Q3 and projects 318,000 Signatera tests, up 57% YoY. Natera's stock is up 77% YTD and 111% over the past year, but is considered overvalued by InvestingPro. Recent Q2 revenue of $753M exceeded expectations, and multiple analysts have raised price targets.

Hedge fund manager Stanley Druckenmiller's largest position is Natera (NTRA), a healthcare company specializing in DNA analysis for diagnostics. Natera reported 37.7% revenue growth last quarter, driven by increased test adoption. The stock has surged 250% over five years but trades at a high P/S ratio of 21, raising concerns about valuation.

Sheena Jonathan sold 3,150 shares of Natera, Inc. (NTRA) at an average of $410.55 ($406.50–$416.67, $1.29M total) across 8 trades on 2026-10-21 under a Rule 10b5-1 trading plan.

Analysts made several calls on Friday. Roth initiated Natera and Guardant Health with buy ratings, targeting $475 and growth respectively. PhillipCapital upgraded SpaceX to buy with a $250 price target. Seaport reiterated Nvidia as sell due to competitive pressures. Barclays initiated Rush Street Interactive at overweight. Piper Sandler downgraded Deckers to underweight. Jefferies upgraded MSC Industrial to buy. Citizens initiated Microbot Medical at market outperform.

Wall Street analyst research calls for Friday include upgrades for Hess Midstream LP (HESM) to Outperform, MSC Industrial (MSM) to Overweight, and SpaceX (SPCX) to Buy. Downgrades include Deckers Outdoor (DECK) to Underweight, Globe Life (GL) to Neutral, and NVR (NVR) to Underperform. Initiations include Guardant Health (GH) and Natera (NTRA) with Buy ratings. Markets saw declines, with Nasdaq down 2.6% and Treasury yields dropping sharply.

Roth/MKM initiated Natera (NTRA) with a buy rating and $475 price target, citing its oncology diagnostics pipeline and growth potential. The stock is up 106% year-to-date. Natera's Q2 revenue exceeded expectations at $753M, prompting raised guidance. Analysts highlight MRD testing and women's health as growth drivers.

Natera director and co-founder Jonathan Sheena sold 1,580 shares for $603,710 under a 10b5-1 plan. Natera shares trade near a 52-week high, up 117% over the past year. The company reported Q2 revenue of $753M, beating expectations. Analysts raised price targets, citing strong growth in MRD testing.

Sheena Jonathan sold 1,500 indirectly-held shares of Natera, Inc. (NTRA) at an average of $402.47 ($398.95–$409.36, $0.60M total) across 12 trades on 2026-10-16 under a Rule 10b5-1 trading plan.